Dexlansoprazole
Encyclopedia
Dexlansoprazole is a proton pump inhibitor
that is marketed by Takeda Pharmaceuticals. Chemically, it is an enantiomer
of lansoprazole
. The compound was launched in the US for use in the treatment and maintenance of patients with erosive oesophagitis and non-erosive gastro-oesophageal reflux disease (GERD or GORD). Dexlansoprazole was approved by the U.S. Food and Drug Administration (FDA) on January 30, 2009.
lansoprazole is applied orally, 80% of the circulating drug is dexlansoprazole. Moreover, both enantiomers have a similar effect on the proton pump. Consequently, the main advantage of Kapidex is not the enantiopure substance, but the pharmaceutical formulation
.
Kapidex is based on a dual release technology, with the first quick release producing a plasma peak concentration about one hour after application, and the second retarded release producing another peak about four hours later. , clinical relevance of this form of release has yet to be shown.
) and Kadian (morphine sulfate), which have very different uses from Kapidex and from each other.
On March 4, 2010, the FDA has approved a name change for Kapidex to avoid confusion with the two other medications. Effective in late April 2010, Takeda Pharmaceuticals North America began marketing Kapidex under the new name Dexilant.
Proton pump inhibitor
Proton-pump inhibitors are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available today. The group followed and has largely superseded another group of pharmaceuticals with similar...
that is marketed by Takeda Pharmaceuticals. Chemically, it is an enantiomer
Enantiomer
In chemistry, an enantiomer is one of two stereoisomers that are mirror images of each other that are non-superposable , much as one's left and right hands are the same except for opposite orientation. It can be clearly understood if you try to place your hands one over the other without...
of lansoprazole
Lansoprazole
Lansoprazole is a proton-pump inhibitor which prevents the stomach from producing gastric acid. It is manufactured by a number of companies worldwide under several brand names . It was first approved by the U.S...
. The compound was launched in the US for use in the treatment and maintenance of patients with erosive oesophagitis and non-erosive gastro-oesophageal reflux disease (GERD or GORD). Dexlansoprazole was approved by the U.S. Food and Drug Administration (FDA) on January 30, 2009.
Pharmacokinetics
After racemicRacemic
In chemistry, a racemic mixture, or racemate , is one that has equal amounts of left- and right-handed enantiomers of a chiral molecule. The first known racemic mixture was "racemic acid", which Louis Pasteur found to be a mixture of the two enantiomeric isomers of tartaric acid.- Nomenclature :A...
lansoprazole is applied orally, 80% of the circulating drug is dexlansoprazole. Moreover, both enantiomers have a similar effect on the proton pump. Consequently, the main advantage of Kapidex is not the enantiopure substance, but the pharmaceutical formulation
Pharmaceutical formulation
Pharmaceutical formulation, in pharmaceutics, is the process in which different chemical substances, including the active drug, are combined to produce a final medicinal product.-Stages and timeline:...
.
Kapidex is based on a dual release technology, with the first quick release producing a plasma peak concentration about one hour after application, and the second retarded release producing another peak about four hours later. , clinical relevance of this form of release has yet to be shown.
Naming confusion
Since Kapidex was approved in January 2009, there have been reports of dispensing errors because of confusion with the drugs Casodex (bicalutamideBicalutamide
Bicalutamide is an oral non-steroidal anti-androgen used in the treatment of prostate cancer and hirsutism...
) and Kadian (morphine sulfate), which have very different uses from Kapidex and from each other.
On March 4, 2010, the FDA has approved a name change for Kapidex to avoid confusion with the two other medications. Effective in late April 2010, Takeda Pharmaceuticals North America began marketing Kapidex under the new name Dexilant.
External links
- DEXILANT (product's website)
- Takeda Pharmaceuticals (manufacturer's website)